---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004775"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:38.018724+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Predictive Oncology Q2 net loss $3.2M on revenue $0.3M; enters biomarker discovery market

## Summary
- Net loss of $3.2M ($0.68 per share) on revenue of $278,722, down 43% YoY from $490K.
- Cash and equivalents $5.3M at June 30, 2024; raised $3.1M net from ATM and $1.3M post-quarter from warrants.
- Entering biomarker discovery market after successful ovarian cancer study with UPMC; market estimated at $51.5B.
- Cost savings initiative to cut cash used in operations by ~20% annually, consolidating Birmingham lab into Pittsburgh.
- Gross margin fell to 45% from 67% due to higher labor costs and lower STREAMWAY system sales.

## SEC filing metadata
- accession: 0001171843-24-004775
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184324004775/0001171843-24-004775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184324004775/f8k_081324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004775
- JSON: https://secwatch.observer/filing/0001171843-24-004775.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004775.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.